Published in Neurology on June 10, 2003
Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct (2007) 0.90
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
Gender effect on time to levodopa-induced dyskinesias. J Neurol (2011) 0.85
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network. Front Neurol (2014) 0.84
Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis (2012) 0.83
DAT1 polymorphism determines L-DOPA effects on learning about others' prosociality. PLoS One (2013) 0.81
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord (2011) 0.77
Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients. Eur J Clin Pharmacol (2016) 0.76
Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord (2011) 0.76
New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis (2011) 0.76
Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent regionally selective, bimodal effects on striatal dopamine kinetics in vivo. J Neurochem (2015) 0.75
The psychosis spectrum in Parkinson disease. Nat Rev Neurol (2017) 0.75
Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease. Brain (2014) 0.75
Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease. Mol Neurobiol (2016) 0.75
A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease. BMC Med Genomics (2017) 0.75
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol (1998) 2.72
EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol (2011) 2.63
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
Long-term ambulatory gastric pH monitoring: validation of a new method and effect of H2-antagonists. Gastroenterology (1985) 2.34
High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol (1999) 2.22
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol (2001) 2.20
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol (2011) 2.07
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet (2001) 2.06
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. Fortschr Med Orig (2001) 2.02
[Intercultural differences in the treatment of severely injured patients with poor prognosis. Using the example of a 23-year-old Chinese patient]. Unfallchirurg (2013) 1.98
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 1.96
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes (2000) 1.89
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res (1996) 1.74
The tremor network targeted by successful VIM deep brain stimulation in humans. Neurology (2012) 1.69
High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res (2001) 1.64
GBA-associated PD presents with nonmotor characteristics. Neurology (2011) 1.63
Reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes. Arch Biochem Biophys (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology (2011) 1.58
Transformations towards the normal distribution of broad band spectral parameters of the EEG. Electroencephalogr Clin Neurophysiol (1982) 1.55
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
EEG coherence in Alzheimer disease. Electroencephalogr Clin Neurophysiol (1994) 1.53
Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics (2000) 1.52
Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry (2000) 1.52
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ (2010) 1.52
Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol (2001) 1.51
Cervical dystonia in monozygotic twins: case report and review of the literature. Mov Disord (2001) 1.51
A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release (2006) 1.51
Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D₃ analogue in polymorphic light eruption. Br J Dermatol (2011) 1.50
Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol (2008) 1.46
Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol (2000) 1.45
Endovascularly or surgically treated vertebral artery and posterior inferior cerebellar artery aneurysms: clinical analysis and results. Zentralbl Neurochir (2005) 1.45
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther (2008) 1.44
Three cases of CLIPPERS: a serial clinical, laboratory and MRI follow-up study. J Neurol (2011) 1.43
Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurol (2013) 1.43
Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol (2012) 1.41
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer (2000) 1.41
A case of amyotrophic lateral sclerosis with a very slow progression over 44 years. Neuromuscul Disord (2001) 1.40
Functional outcome after surgical treatment of intramedullary spinal cord tumors: experience with 78 patients. Spinal Cord (2005) 1.39
Spinocerebellar ataxia type 6: evidence for a strong founder effect among German families. Neurology (1999) 1.39
Immunosuppressive properties of cyclosporin metabolites. Lancet (1989) 1.39
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology (2008) 1.39
Hydrogen peroxide in hepatic microsomes. Methods Enzymol (1978) 1.38
Three-dimensional imaging of magnetic domains. Nat Commun (2010) 1.38
Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep (2000) 1.37
Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease. Eur J Neurosci (2005) 1.33
Metabolic fate of oxidized guanine ribonucleotides in mammalian cells. Biochemistry (1999) 1.30
In situ observation of living pericytes in rat retinal capillaries. Microvasc Res (1998) 1.30
The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Hum Genet (1994) 1.30
Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res (1993) 1.29
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry (2006) 1.25
Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol (1998) 1.24
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther (1999) 1.23
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1992) 1.22
Analysis of the adolescent growth spurt using smoothing spline functions. Ann Hum Biol (1978) 1.22
A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol (2006) 1.22
Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol (2001) 1.21
Sex differences in brain activation pattern during a visuospatial cognitive task: a functional magnetic resonance imaging study in healthy volunteers. Neurosci Lett (2003) 1.20
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost (2005) 1.19
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J (2005) 1.19
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics (2001) 1.18
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain (2000) 1.18
A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet (1999) 1.18
Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants. Neurology (2004) 1.17